Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Second-Line ADMs & CV Events in T2D

JAMA Netw Open; ePub 2018 Dec 21; O’Brien, et al

Publish date:: January 8, 2019

Among adults with type 2 diabetes (T2D) initiating second-line antidiabetic medication (ADM) therapy, the short-term cardiovascular (CV) outcomes of glucagon-like peptide-1 (GLP-1) receptor agonists, sodium-glucose cotransporter 2 (SGLT-2) inhibitors, and dipeptidyl peptidase 4 (DPP-4) inhibitors were similar, a recent study found. The cohort study included 132,737 adults (aged 45-64 years) with T2D and examined the association of second-line ADM classes with major adverse CV events. Researchers found:

GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT-2 inhibitors were associated with similar CV outcomes.

Sulfonylureas and basal insulin were associated with comparatively higher CV risk.
Clinicians may consider prescribing newer ADM classes more routinely after metformin.

Citation:

O’Brien MJ, Karam SL, Wallia A, et al. Association of second-line antidiabetic medications with cardiovascular events among insured adults with type 2 diabetes. JAMA Netw Open. 2018;1(8):e186125. doi:10.1001/jamanetworkopen.2018.6125.

This Week's Must Reads

Consider potential cognitive complications prior to androgen deprivation therapy,

Diabetes raises risk of prostate cancer mortality in obese men,

Salivation inhibition fails to reduce radioiodine toxicity in prostate cancer,

Highest positive surgical margin predicts poor survival after prostatectomy,

Young minority men are underinformed about prostate cancer screening,

Must Reads in Diabetes

PTSD symptom reduction tied to lower risk of type 2 diabetes,

Smoking May Precede Depressive Symptoms in Adults With Type 2 Diabetes,

Depression Undertreated in Black, Hispanic Patients With Diabetes,

Testosterone Therapy to Prevent T2D in Men, Diabetes Care; ePub 2019 Mar 18; Yassin, et al

Patterns of Diabetes Screening During Office Visits, J Am Board Fam Med; 2019 Mar-Apr; Shealy, et al